Abstract Number: 175 • 2015 ACR/ARHP Annual Meeting
Correlating Semiquantitative Ultrasound Scores with Measured Synovial Thickness
Background/Purpose: In studies of rheumatoid arthritis using ultrasonography (US), findings of synovial thickening are often reported in semiquantitative scores. For synovial biopsies of small joints,…Abstract Number: 1314 • 2015 ACR/ARHP Annual Meeting
Quantitative MRI Measurement of Tenosynovitis Demonstrates Differing Responses of Synovitis and Tenosynovitis after RA Treatment
Background/Purpose: Inflammation of the tendon sheaths (tenosynovitis) is a recognised component of rheumatoid arthritis (RA). A comprehensive assessment of inflammation will require the inclusion of…Abstract Number: 2270 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Disease: The Hidden Risk in Persons with Rheumatoid Arthritis
Background/Purpose: Despite the fact that patients with rheumatoid arthritis (RA) experience a 50-60% increased risk of developing cardiovascular disease (CVD), substantial gaps remain in the…Abstract Number: 2770 • 2015 ACR/ARHP Annual Meeting
Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study
Background/Purpose: Remission is an important clinical outcome in RA1 and is associated with improved physical function and health-related quality of life.2 Several definitions of remission…Abstract Number: 176 • 2015 ACR/ARHP Annual Meeting
Considerable Discrepancy Between Patient’s Assessment and Ultrasonography Assessment on the Most Affected Joint in Rheumatoid Arthritis
Background/Purpose: Musculoskeletal ultrasonography (US) is a useful tool for the diagnosis and monitoring of rheumatoid arthritis (RA). It is also helpful for promoting patient-clinician communication…Abstract Number: 1487 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Who Have Failed to Disease-Modifying Antirheumatic Drugs: Long Term Results of the Brazilian Cohort
Background/Purpose: Tocilizumab is a humanized monoclonal antibody that binds to IL-6 receptor, blocking its effects. The efficacy and safety of tocilizumab in rheumatoid arthritis (RA)…Abstract Number: 2334 • 2015 ACR/ARHP Annual Meeting
Proof of Concept Study of the Arthritis Health Journal: An Online Tool to Promote Self-Monitoring in People with Rheumatoid Arthritis (RA)
Background/Purpose: Patient passports have been used in chronic diseases to promote active involvement of patients in their care. In RA, patient monitoring of their disease…Abstract Number: 3109 • 2015 ACR/ARHP Annual Meeting
Single Cell Gene Expression in Classical Monocytes Correlates with Treatment Response Groups to TNF-Alpha Inhibition in Rheumatoid Arthritis
Background/Purpose: In management of rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy,…Abstract Number: 433 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Background/Purpose: A majority of RA patients who switch from a tumor necrosis factor inhibitor (TNFi) to another biologic disease-modifying anti-rheumatic drug (DMARD) are TNFi cyclers…Abstract Number: 1529 • 2015 ACR/ARHP Annual Meeting
Trabecular Bone Score in Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is associated with low bone mass and increased risk of fragility fractures that are related to patient characteristics, treatments and disease…Abstract Number: 2588 • 2015 ACR/ARHP Annual Meeting
Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women
Background/Purpose : Patients with rheumatoid arthritis (RA) are predominantly female, smokers and positive for autoantibodies, rheumatoid factor and antibodies to citrullinated peptides. The oncoprotein survivin…Abstract Number: 3199 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
Background/Purpose: In RA patients, different randomized clinical trials have showed that the efficacy of reduced dose of RTX either initially and for subsequent courses (DANCER,…Abstract Number: 435 • 2015 ACR/ARHP Annual Meeting
Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-α Therapy: Results from a Phase 3 Study (RCT)
Background/Purpose : Sarilumab, a human monoclonal antibody directed against the IL-6 receptor, in combination with non-biologic DMARDs, demonstrated efficacy in the TARGET RCT (NCT01709578). TEAEs…Abstract Number: 1543 • 2015 ACR/ARHP Annual Meeting
Traditional Risk Score Underestimates the Cardiovascular Risk in Rheumatoid Arthritis Patients
Background/Purpose: An increased incidence of cardiovascular (CV) mortality has been reported in patients with rheumatoid arthritis (RA). Adequate stratification of the CV risk is an…Abstract Number: 2591 • 2015 ACR/ARHP Annual Meeting
Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 56
- Next Page »